Base de dados : MEDLINE
Pesquisa : D02.033.800.813.550 [Categoria DeCS]
Referências encontradas : 3662 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 367 ir para página                         

  1 / 3662 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:29236929
[Au] Autor:Silva RED; Carvalho JP; Ramalho DB; Senna MCR; Moreira HSA; Rabello A; Cota E; Cota G
[Ad] Endereço:Centro de Referência em Leishmanioses, Pesquisa Clínica e Políticas Públicas em Doenças Infecto-Parasitárias, Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz-Fiocruz, Belo Horizonte, MG, Brasil.
[Ti] Título:Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment.
[So] Source:Mem Inst Oswaldo Cruz;113(2):71-79, 2018 Feb.
[Is] ISSN:1678-8060
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:BACKGROUND Despite its recognised toxicity, antimonial therapy continues to be the first-line drug for cutaneous leishmaniasis (CL) treatment. Intralesional administration of meglumine antimoniate (MA) represents an alternative that could reduce the systemic absorption of the drug and its side effects. OBJECTIVES This study aims to validate the standard operational procedure (SOP) for the intralesional infiltration of MA for CL therapy as the first step before the assessment of efficacy and safety related to the procedure. METHODS The SOP was created based on 21 trials retrieved from the literature, direct monitoring of the procedure and consultation with experts. This script was submitted to a formal computer-aided inspection to identify readability, clarity, omission, redundancy and unnecessary information (content validation). For criterion and construct validations, the influence of critical condition changes (compliance with the instructions and professional experience) on outcome conformity (saturation status achievement), tolerability (pain referred) and safety (bleeding) were assessed. FINDINGS The median procedure length was 12 minutes and in 72% of them, patients classified the pain as mild. The bleeding was also classified as mild in 96.6% of the procedures. Full compliance with the SOP was observed in 66% of infiltrations. Despite this, in 100% of the inspected procedures, lesion saturation was observed at the end of infiltration, which means that it tolerates some degree of modification in its execution (robustness) without prejudice to the result. CONCLUSIONS The procedure is reproducible and can be used by professionals without previous training with high success and safety rates.
[Mh] Termos MeSH primário: Antiprotozoários/administração & dosagem
Protocolos Clínicos/normas
Injeções Intralesionais
Leishmaniose Cutânea/tratamento farmacológico
Meglumina/administração & dosagem
Compostos Organometálicos/administração & dosagem
[Mh] Termos MeSH secundário: Seres Humanos
Injeções Intralesionais/efeitos adversos
Injeções Intralesionais/métodos
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Antiprotozoal Agents); 0 (Organometallic Compounds); 6HG8UB2MUY (Meglumine); 75G4TW236W (meglumine antimoniate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE


  2 / 3662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29324838
[Au] Autor:Travi BL; Cordeiro-da-Silva A; Dantas-Torres F; Miró G
[Ad] Endereço:Department of Internal Medicine-Division of Infectious Diseases, University of Texas Medical Branch, Galveston, Texas, United States of America.
[Ti] Título:Canine visceral leishmaniasis: Diagnosis and management of the reservoir living among us.
[So] Source:PLoS Negl Trop Dis;12(1):e0006082, 2018 01.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This article reviews essential topics of canine visceral leishmaniasis (CVL) due to Leishmania infantum infection. It focuses on the current serological and molecular diagnostic methods used in epidemiological research and veterinary clinics to diagnose CVL and includes new point-of-care (POC) tests under development. The efficacy of different treatment regimens on the clinical improvement and infectiousness of dogs is also addressed. In the last section, the review provides a critical appraisal of the effectiveness of different control measures that have been implemented to curb disease transmission.
[Mh] Termos MeSH primário: Antiprotozoários/uso terapêutico
Doenças do Cão/diagnóstico
Doenças do Cão/tratamento farmacológico
Leishmaniose Visceral/diagnóstico
Leishmaniose Visceral/veterinária
Técnicas de Diagnóstico Molecular
[Mh] Termos MeSH secundário: Alopurinol/uso terapêutico
Animais
Reservatórios de Doenças/parasitologia
Reservatórios de Doenças/veterinária
Doenças do Cão/parasitologia
Cães
Leishmania infantum/efeitos dos fármacos
Leishmaniose Visceral/parasitologia
Meglumina/uso terapêutico
Compostos Organometálicos/uso terapêutico
Fosforilcolina/análogos & derivados
Fosforilcolina/uso terapêutico
Sistemas Automatizados de Assistência Junto ao Leito
Testes Sorológicos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiprotozoal Agents); 0 (Organometallic Compounds); 107-73-3 (Phosphorylcholine); 53EY29W7EC (miltefosine); 63CZ7GJN5I (Allopurinol); 6HG8UB2MUY (Meglumine); 75G4TW236W (meglumine antimoniate)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180130
[Lr] Data última revisão:
180130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0006082


  3 / 3662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Marzochi, Mauro Célio de Almeida
Texto completo SciELO Brasil
[PMID]:29211245
[Au] Autor:Brahim LR; Valete-Rosalino CM; Antônio LF; Pimentel MIF; Lyra MR; Paes LEC; Costa ADD; Vieira IF; Dias CMG; Duque MCO; Marzochi MCA; Schubach AO
[Ad] Endereço:Fundação Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laboratório de Pesquisa Clínica e Vigilância em Leishmanioses, Rio de Janeiro, RJ, Brasil.
[Ti] Título:Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013).
[So] Source:Mem Inst Oswaldo Cruz;112(12):838-843, 2017 Dec.
[Is] ISSN:1678-8060
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: American tegumentary leishmaniasis (ATL) is a non-lethal parasitic disease that presents with cutaneous (CL) and mucosal (ML) clinical forms. ATL treatment aims at healing the lesions and preventing the development of the late mucosal form. Systemic meglumine antimoniate (MA) therapy with 10-20 mg Sb5+/kg/day is the first choice of treatment. However, alternative therapies using 5 mg Sb5+/kg/day or intralesional (IL) MA are the usual regimens at the National Institute of Infectious Diseases (NIID), Rio de Janeiro, Brazil. OBJECTIVES: To evaluate lethality and the incidence of relapse and development of late ML in CL patients treated at NIID from 2001 until 2013. METHODS: Data were recovered from records of all ATL patients diagnosed during that period. FINDINGS: Out of 777 patients, 753 were treated with MA (96.9%). Of those, 89.1% received alternative therapy of 9.9% IL and 79.2% systemic 5 mg Sb5+/kg/day. Some patients required 1-3 additional courses of treatment, thus making a total of 997 courses; 85.2% of them were subjected to alternative therapies. Lethality was 0.1%, relapse incidence 5.8%, and late ML incidence 0.25%. As a final outcome for the 777 patients, 95.9% were cured, 0.1% died and 4.0% were not able to follow-up. MAIN CONCLUSIONS: Alternative MA schedules resulted in low lethality without increase of relapse or late ML incidence.
[Mh] Termos MeSH primário: Antiprotozoários/administração & dosagem
Leishmaniose Cutânea/tratamento farmacológico
Meglumina/administração & dosagem
Compostos Organometálicos/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Estudos de Coortes
Feminino
Seres Humanos
Incidência
Injeções Intralesionais
Leishmaniose Cutânea/mortalidade
Masculino
Meia-Idade
Recidiva
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiprotozoal Agents); 0 (Organometallic Compounds); 6HG8UB2MUY (Meglumine); 75G4TW236W (meglumine antimoniate)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171227
[Lr] Data última revisão:
171227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE


  4 / 3662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29079664
[Au] Autor:Ghafoori E; Kholmovski EG; Thomas S; Silvernagel J; Angel N; Hu N; Dosdall DJ; MacLeod R; Ranjan R
[Ad] Endereço:From the Department of Bioengineering (E.G., J.S., N.A., D.J.D., R.M., R.R.), Cardiovascular Medicine (E.G., J.S., N.A., R.R.), UCAIR, Department of Radiology and Imaging Sciences (E.G.K.), Department of Medicine (S.T., N.H., R.R.), and Department of Surgery (D.J.D.), University of Utah, Salt Lake C
[Ti] Título:Characterization of Gadolinium Contrast Enhancement of Radiofrequency Ablation Lesions in Predicting Edema and Chronic Lesion Size.
[So] Source:Circ Arrhythm Electrophysiol;10(11), 2017 Nov.
[Is] ISSN:1941-3084
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Magnetic resonance imaging (MRI) has been used to acutely visualize radiofrequency ablation lesions, but its accuracy in predicting chronic lesion size is unknown. The main goal of this study was to characterize different areas of enhancement in late gadolinium enhancement MRI done immediately after ablation to predict acute edema and chronic lesion size. METHODS AND RESULTS: In a canine model (n=10), ventricular radiofrequency lesions were created using ThermoCool SmartTouch (Biosense Webster) catheter. All animals underwent MRI (late gadolinium enhancement and T2-weighted edema imaging) immediately after ablation and after 1, 2, 4, and 8 weeks. Edema, microvascular obstruction, and enhanced volumes were identified in MRI and normalized to chronic histological volume. Immediately after contrast administration, the microvascular obstruction region was 3.2±1.1 times larger than the chronic lesion volume in acute MRI. Even 60 minutes after contrast administration, edema was 8.7±3.31 times and the enhanced area 6.14±2.74 times the chronic lesion volume. Exponential fit to the microvascular obstruction volume was found to be the best predictor of chronic lesion volume at 26.14 minutes (95% prediction interval, 24.35-28.11 minutes) after contrast injection. The edema volume in late gadolinium enhancement correlated well with edema volume in T2-weighted MRI with an of 0.99. CONCLUSION: Microvascular obstruction region on acute late gadolinium enhancement images acquired 26.1 minutes after contrast administration can accurately predict the chronic lesion volume. We also show that T1-weighted MRI images acquired immediately after contrast injection accurately shows edema resulting from radiofrequency ablation.
[Mh] Termos MeSH primário: Ablação por Cateter/efeitos adversos
Cicatriz/diagnóstico por imagem
Meios de Contraste/administração & dosagem
Edema Cardíaco/diagnóstico por imagem
Ventrículos do Coração/cirurgia
Imagem por Ressonância Magnética
Meglumina/análogos & derivados
Compostos Organometálicos/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Biópsia
Cicatriz/etiologia
Cicatriz/patologia
Circulação Coronária
Cães
Edema Cardíaco/etiologia
Edema Cardíaco/patologia
Ventrículos do Coração/diagnóstico por imagem
Ventrículos do Coração/patologia
Meglumina/administração & dosagem
Microcirculação
Modelos Animais
Valor Preditivo dos Testes
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contrast Media); 0 (Organometallic Compounds); 15G12L5X8K (gadobenic acid); 6HG8UB2MUY (Meglumine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171121
[Lr] Data última revisão:
171121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171029
[St] Status:MEDLINE


  5 / 3662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28945058
[Ti] Título:Control of visceral leishmaniasis in Somalia: achievements in a challenging scenario, 2013­2015.
[Ti] Título:Lutte contre la leishmaniose viscérale en Somalie: les progrès accomplis dans un contexte difficile, 2013-2015..
[So] Source:Wkly Epidemiol Rec;92(35):566-72, 2017 09 22.
[Is] ISSN:0049-8114
[Cp] País de publicação:Switzerland
[La] Idioma:eng; fre
[Mh] Termos MeSH primário: Gluconato de Antimônio e Sódio/uso terapêutico
Leishmaniose Visceral/tratamento farmacológico
Leishmaniose Visceral/epidemiologia
Leishmaniose Visceral/prevenção & controle
[Mh] Termos MeSH secundário: Distribuição por Idade
Instituições de Assistência Ambulatorial/estatística & dados numéricos
Antiprotozoários/uso terapêutico
Feminino
Seres Humanos
Incidência
Leishmaniose Visceral/diagnóstico
Masculino
Meglumina/uso terapêutico
Compostos Organometálicos/uso terapêutico
Distribuição por Sexo
Somália/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiprotozoal Agents); 0 (Organometallic Compounds); 6HG8UB2MUY (Meglumine); 75G4TW236W (meglumine antimoniate); V083S0159D (Antimony Sodium Gluconate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170926
[St] Status:MEDLINE


  6 / 3662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28926630
[Au] Autor:Brito NC; Rabello A; Cota GF
[Ad] Endereço:Pesquisas Clínicas e Políticas Públicas em Doenças Infecto-Parasitárias-Centro de Pesquisas René Rachou-Fundação Oswaldo Cruz, Fiocruz, Belo Horizonte, Minas Gerais, Brazil.
[Ti] Título:Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.
[So] Source:PLoS One;12(9):e0184777, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The mainstays of cutaneous leishmaniasis (CL) treatment, in several world regions, are pentavalent antimony (Sbv) compounds administered parenterally, despite their recognized toxicity, which requires frequent laboratory monitoring and complicates their use in areas with scarce infrastructure. As result of these drawbacks, the WHO Expert Committee on leishmaniasis has expanded the recommendations for the use of local therapies, including Sbv intralesional infiltration (IL-Sbv), as CL therapy alternatives even in the New World. However, the efficacy of these approaches has never been compiled. The aim of this study was to critically and systematically assess the efficacy of IL-Sbv for CL treatment. METHODOLOGY: The PRISMA guidelines for systematic reviews and the Cochrane manual were followed. The sources used were the MEDLINE and LILACS databases and the International Clinical Trials Registry Platform of the World Health Organization. The outcome of interest was a clinical cure, defined as complete re-epithelialization of all lesions. The IL-Sbv pooled cure rate was estimated for several subgroups and direct comparisons were performed when possible. RESULTS: Thirty nine articles (40 studies) involving 5679 patients treated with IL-Sbv infiltration were included. In direct comparison, only three studies involving 229 patients compared IL-Sbv infiltration versus placebo and no difference was observed (OR: 1,9; 95%IC 0,93 to 3,82) based on cure rate 69.6% (95%CI 17.6-96.1%) and 83,2% (95%CI 66-92.7%) for placebo and IL-Sbv, respectively. In an alternative and non-comparative analysis, gathering all study arms using the intervention, the pooled IL-Sbv efficacy rate was 75% (95%CI 68-81%). In the Old World, the observed overall IL-Sbv efficacy rate was 75% (95%CI 66-82%), and the cure rates were significantly higher with sodium stibogluconate (SSG) than with meglumine antimoniate (MA): 83% (95%CI 75-90%) versus 68% (95%CI 54-79%), p = 0.03. Studies directly comparing IL-Sbv with topical 15% paromomycin ointment, IL hypertonic saline, radiofrequency-induced heat therapy, topical trichloroacetic acid and cryotherapy showed no significant difference in efficacy between the interventions. The analyses suggested a higher efficacy of IL-Sbv combined with cryotherapy (81.8%, 95%IC 62.4-92.4%) when compared with IL-Sbv alone (53.3%, 95%IC 46.1-66%), OR: 3.14 (95%CI 1.1-8.9), p = 0.03. In the New World, the global IL-Sbv efficacy was 77%(95%CI 66-85%). In contrast with the Old World, a significant difference favoring MA in relation to SSG was observed: 61% (95%CI 49-73%) versus 82% (95%CI 70-89%).By comparing IL infiltration schedules, it was determined that patients submitted to IL-Sbv treatments longer than 14 days had higher cure rates. CONCLUSIONS: Despite the high heterogeneity and low methodological quality of studies, an indirect comparison shows that the antimony infiltration efficacy rate is similar to that reported for antimony systemic use. The evidence gathered thus far is insufficient to identify the ideal IL therapeutic regime or estimate the rates of adverse events and mucosal late complications.
[Mh] Termos MeSH primário: Antimônio/uso terapêutico
Antiprotozoários/uso terapêutico
Leishmaniose Cutânea/tratamento farmacológico
[Mh] Termos MeSH secundário: Antimônio/química
Gluconato de Antimônio e Sódio/uso terapêutico
Antiprotozoários/química
Crioterapia
Bases de Dados Factuais
Seres Humanos
Injeções Intralesionais
Leishmaniose Cutânea/patologia
Meglumina/uso terapêutico
Compostos Organometálicos/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiprotozoal Agents); 0 (Organometallic Compounds); 6HG8UB2MUY (Meglumine); 75G4TW236W (meglumine antimoniate); 9IT35J3UV3 (Antimony); V083S0159D (Antimony Sodium Gluconate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170920
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0184777


  7 / 3662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28763499
[Au] Autor:Andrade PHS; Lobo IMF; da Silva WB
[Ad] Endereço:Universidade Federal de Sergipe, São Cristóvão, Sergipe, Brazil.
[Ti] Título:Risk factors for adverse drug reactions in pediatric inpatients: A cohort study.
[So] Source:PLoS One;12(8):e0182327, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The present study aims to identify the risk factors for adverse drug reactions (ADR) in pediatric inpatients. METHODS: A prospective cohort study in one general pediatric ward in a hospital in Northeast Brazil was conducted in two stages: the first stage was conducted between August 17th and November 6th, 2015, and the second one between March 1st and August 25th, 2016. We included children aged 0-14 years 11 months hospitalized with a minimum stay of 48 hours. Observed outcomes were the ADR occurrence and the time until the first ADR observed. In the univariate analysis, the time to the first ADR was compared among groups using a log-rank test. For the multivariate analysis, the Cox regression model was used. RESULTS: A total of 173 children (208 admissions) and 66 ADR classified as "definite" and "probable" were identified. The incidence rate was 3/100 patient days. The gastro-intestinal system disorders were the main ADR observed (28.8%). In addition, 22.7% of the ADR were related to antibacterials for systemic use and 15.2% to general anesthesia. Prior history of ADR of the child [hazard ratio (HR) 2.44; 95% confidence interval (CI) 1.19-5.00], the use of meglumine antimonate (HR 4.98; 95% CI 1.21-20.54), antibacterial for systemic use (HR 2.75; 95% CI 1.08-6.98) and antiepileptic drugs (HR 3.84; 95% CI 1.40-10.56) were identified risk factors for ADR. CONCLUSIONS: We identified as risk factors the prior history of ADR of the child and the use of meglumine antimonate, antibacterial for systemic use and antiepileptic drugs.
[Mh] Termos MeSH primário: Antibacterianos/efeitos adversos
Anticonvulsivantes/efeitos adversos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Meglumina/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Sistemas de Notificação de Reações Adversas a Medicamentos
Anestesia Geral
Brasil
Criança
Pré-Escolar
Clonazepam/efeitos adversos
Estudos de Coortes
Fibrose Cística/tratamento farmacológico
Dipirona/efeitos adversos
Feminino
Gastroenteropatias/complicações
Gastroenteropatias/tratamento farmacológico
Hospitalização
Hospitais Pediátricos
Seres Humanos
Lactente
Recém-Nascido
Pacientes Internados
Masculino
Omeprazol/efeitos adversos
Pediatria
Projetos Piloto
Modelos de Riscos Proporcionais
Análise de Regressão
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anticonvulsants); 5PE9FDE8GB (Clonazepam); 6429L0L52Y (Dipyrone); 6HG8UB2MUY (Meglumine); KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170802
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182327


  8 / 3662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28705875
[Au] Autor:Andrews CM; Srinivasan NT; Rosmini S; Bulluck H; Orini M; Jenkins S; Pantazis A; McKenna WJ; Moon JC; Lambiase PD; Rudy Y
[Ad] Endereço:From the Department of Biomedical Engineering (C.M.A., Y.R.) and Cardiac Bioelectricity and Arrhythmia Center (C.M.A., Y.R.), Washington University, St. Louis, MO; Department of Medicine, Cardiovascular Division, Washington University in St. Louis, MO (Y.R.); Department of Cardiac Electrophysiology,
[Ti] Título:Electrical and Structural Substrate of Arrhythmogenic Right Ventricular Cardiomyopathy Determined Using Noninvasive Electrocardiographic Imaging and Late Gadolinium Magnetic Resonance Imaging.
[So] Source:Circ Arrhythm Electrophysiol;10(7), 2017 Jul.
[Is] ISSN:1941-3084
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a significant cause of sudden cardiac death in the young. Improved noninvasive assessment of ARVC and better understanding of the disease substrate are important for improving patient outcomes. METHODS AND RESULTS: We studied 20 genotyped ARVC patients with a broad spectrum of disease using electrocardiographic imaging (a method for noninvasive cardiac electrophysiology mapping) and advanced late gadolinium enhancement cardiac magnetic resonance scar imaging. Compared with 20 healthy controls, ARVC patients had longer ventricular activation duration (median, 52 versus 42 ms; =0.007) and prolonged mean epicardial activation-recovery intervals (a surrogate for local action potential duration; median, 275 versus 241 ms; =0.014). In these patients, we observed abnormal and varied epicardial activation breakthrough locations and regions of nonuniform conduction and fractionated electrograms. Nonuniform conduction and fractionated electrograms were present in the early concealed phase of ARVC. Electrophysiological abnormalities colocalized with late gadolinium enhancement scar, indicating a relationship with structural disease. Premature ventricular contractions were common in ARVC patients with variable initiation sites in both ventricles. Premature ventricular contraction rate increased with exercise, and within anatomic segments, it correlated with prolonged repolarization, electric markers of scar, and late gadolinium enhancement (all <0.001). CONCLUSIONS: Electrocardiographic imaging reveals electrophysiological substrate properties that differ in ARVC patients compared with healthy controls. A novel mechanistic finding is the presence of repolarization abnormalities in regions where ventricular ectopy originates. The results suggest a potential role for electrocardiographic imaging and late gadolinium enhancement in early diagnosis and noninvasive follow-up of ARVC patients.
[Mh] Termos MeSH primário: Displasia Arritmogênica Ventricular Direita/diagnóstico
Eletrocardiografia/métodos
Imagem por Ressonância Magnética/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Displasia Arritmogênica Ventricular Direita/fisiopatologia
Estudos de Casos e Controles
Cicatriz/fisiopatologia
Meios de Contraste
Diagnóstico Precoce
Feminino
Genótipo
Sistema de Condução Cardíaco/fisiopatologia
Seres Humanos
Masculino
Meglumina
Meia-Idade
Compostos Organometálicos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contrast Media); 0 (Organometallic Compounds); 6HG8UB2MUY (Meglumine); L0ND3981AG (gadoterate meglumine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170715
[St] Status:MEDLINE


  9 / 3662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28703380
[Au] Autor:García M; Scull R; Satyal P; Setzer WN; Monzote L
[Ad] Endereço:Parasitology Department, Institute of Tropical Medicine "Pedro Kouri", Havana, Cuba.
[Ti] Título:Chemical Characterization, Antileishmanial Activity, and Cytotoxicity Effects of the Essential Oil from Leaves of Pluchea carolinensis (Jacq.) G. Don. (Asteraceae).
[So] Source:Phytother Res;31(9):1419-1426, 2017 Sep.
[Is] ISSN:1099-1573
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Current strategies to control leishmaniasis are mainly based on chemotherapy. However, none of the available drugs can be considered to be ideal to treat this disease. Because of the hydrophobic nature and bioactivities of their components, essential oils (EOs) can be considered as important sources for developing agents against intracellular pathogens, such as Leishmania parasites. In this study, we report the chemical characterization, antileishmanial activities, and cytotoxicity effect of the EO from Pluchea carolinensis (Jacq.) G. Don. (Asteraceae). Chemical analysis revealed that EO from aerial part from P. carolinensis is composed of 44 compounds. The main component was selin-11-en-4α-ol, which made up 51.0%. In vitro antileishmanial studies showed that P. carolinensis EO inhibited the growth of promastigotes (IC  = 24.7 ± 7.1 µg/mL) and amastigotes (IC  = 6.2 ± 0.1 µg/mL) of Leishmania amazonensis, while cytotoxicity evaluation revealed fivefold higher values than those for the parasites. In a model of experimental cutaneous leishmaniasis in BALB/c mice, five doses of EO at 30 mg/kg by intralesional route demonstrated smaller lesion size and parasite burden (p < 0.05) compared with animals treated with Glucantime® and untreated mice. In conclusion, in vitro and in vivo results showed the potentialities of EO from P. carolinensis with the future possibility of a new alternative in the treatment for leishmaniasis. Copyright © 2017 John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Antiprotozoários/farmacologia
Asteraceae/química
Leishmaniose Cutânea/tratamento farmacológico
Óleos Voláteis/farmacologia
[Mh] Termos MeSH secundário: Animais
Feminino
Leishmania/efeitos dos fármacos
Leishmania mexicana/efeitos dos fármacos
Meglumina/farmacologia
Camundongos
Camundongos Endogâmicos BALB C
Compostos Organometálicos/farmacologia
Folhas de Planta/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiprotozoal Agents); 0 (Oils, Volatile); 0 (Organometallic Compounds); 6HG8UB2MUY (Meglumine); 75G4TW236W (meglumine antimoniate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170714
[St] Status:MEDLINE
[do] DOI:10.1002/ptr.5869


  10 / 3662 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28683109
[Au] Autor:Kirchner J; Sawicki LM; Deuschl C; Grüneisen J; Beiderwellen K; Lauenstein TC; Herrmann K; Forsting M; Heusch P; Umutlu L
[Ad] Endereço:Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Dusseldorf, Germany.
[Ti] Título:18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine.
[So] Source:PLoS One;12(7):e0180349, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To evaluate the added value of the application of the liver-specific contrast phase of Gadobenate dimeglumine (Gd-BOPTA) for detection and characterization of liver lesions in 18F-FDG PET/MRI. METHODS: 41 patients with histologically confirmed solid tumors and known / suspected liver metastases or not classifiable lesions in 18F-FDG PET/CT were included in this study. All patients underwent a subsequent Gd-BOPTA enhanced 18F-FDG PET/MRI examination. MRI without liver-specific contrast phase (MRI1), MRI with liver-specific contrast phase (MRI2), 18F-FDG PET/MRI without liver-specific contrast phase (PET/MRI1) and with liver-specific contrast phase (PET/MRI2) were separately evaluated for suspect lesions regarding lesion dignity, characterization, conspicuity and confidence. RESULTS: PET/MRI datasets enabled correct identification of 18/18 patients with malignant lesions; MRI datasets correctly identified 17/18 patients. On a lesion-based analysis PET/MRI2 provided highest accuracy for differentiation of lesions into malignant and benign lesions of 98% and 100%. Respective values were 95% and 100% for PET/MRI1, 93% and 96% for MRI2 and 91% and 93% for MRI1. Statistically significant higher diagnostic confidence was found for PET/MRI2 and MRI2 datasets compared to PET/MRI1 and MRI1, respectively (p < 0.001). CONCLUSION: The application of the liver-specific contrast phase in 18F-FDG PET/MRI further increases the diagnostic accuracy and diagnostic confidence for correct assessment of benign and malignant liver lesions.
[Mh] Termos MeSH primário: Carcinoma Hepatocelular/diagnóstico por imagem
Meios de Contraste/farmacocinética
Neoplasias Hepáticas/diagnóstico por imagem
Fígado/diagnóstico por imagem
Imagem por Ressonância Magnética/métodos
Meglumina/análogos & derivados
Compostos Organometálicos/farmacocinética
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Neoplasias da Mama/diagnóstico por imagem
Neoplasias da Mama/metabolismo
Neoplasias da Mama/patologia
Carcinoma Hepatocelular/metabolismo
Carcinoma Hepatocelular/secundário
Colangiocarcinoma/diagnóstico por imagem
Colangiocarcinoma/metabolismo
Colangiocarcinoma/patologia
Neoplasias Colorretais/diagnóstico por imagem
Neoplasias Colorretais/metabolismo
Neoplasias Colorretais/patologia
Feminino
Fluordesoxiglucose F18/farmacocinética
Seres Humanos
Fígado/metabolismo
Fígado/patologia
Neoplasias Hepáticas/metabolismo
Neoplasias Hepáticas/secundário
Masculino
Meglumina/farmacocinética
Melanoma/diagnóstico por imagem
Melanoma/metabolismo
Melanoma/patologia
Meia-Idade
Compostos Radiofarmacêuticos/farmacocinética
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contrast Media); 0 (Organometallic Compounds); 0 (Radiopharmaceuticals); 0Z5B2CJX4D (Fluorodeoxyglucose F18); 15G12L5X8K (gadobenic acid); 6HG8UB2MUY (Meglumine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170707
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0180349



página 1 de 367 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde